Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $148.64, for a total transaction of $2,229,600.00. Following the transaction, the chief executive officer owned 577,133 shares in the company, valued at approximately $85,785,049.12. The trade was a 2.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Monday, August 3rd, Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00.
• On Wednesday, July 1st, Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $126.29, for a total value of $1,894,350.00.

Gilead Sciences Price Performance

Shares of GILD traded down $0.31 during trading hours on Wednesday, hitting $149.61. 4,918,316 shares of the company were exchanged, compared to its average volume of 7,003,209. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29. The company has a market cap of $185.51 billion, a price-to-earnings ratio of -56.03 and a beta of 0.33. The firm’s fifty day moving average is $135.17 and its 200 day moving average is $136.46.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.Gilead Sciences’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.01 earnings per share. On average, equities analysts anticipate that Gilead Sciences, Inc. will post -0.47 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is -122.85%.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a research report on Wednesday, May 20th. Barclays decreased their price target on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 29th. Needham & Company LLC reissued a “buy” rating and set a $170.00 price target on shares of Gilead Sciences in a report on Wednesday, August 5th. Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings lowered Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $158.04.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Zacks upgraded Gilead to a “Strong Buy” (Zacks Rank #1), citing improving earnings prospects. The upgrade could increase buying interest and support the shares. Gilead Upgraded to Strong Buy
• Positive Sentiment: Zacks raised its FY2027 EPS forecast to $9.36 from $9.30, with quarterly estimates also increased slightly to $2.09 for Q1, $2.24 for Q2, $2.43 for Q3 and $2.60 for Q4. The revisions indicate modestly stronger expectations for Gilead’s future profitability.
• Positive Sentiment: FDA approval of Bixlenvo expands Gilead’s HIV portfolio with a single-tablet regimen designed to serve underserved patients. The product could provide an additional source of HIV-related revenue, although commercial adoption will determine its financial impact. Bixlenvo HIV Growth Article
• Neutral Sentiment: Erste Group Bank also raised its forecasts, lifting FY2027 EPS expectations to $9.86 from $9.57 and improving its FY2026 estimate to a loss of $0.45 per share from a loss of $0.75. These changes reinforce improving expectations but remain analyst estimates rather than reported results.
• Neutral Sentiment: GILD is trading near its 52-week high, which reflects strong recent momentum but may also limit the immediate impact of additional positive revisions. Investors may focus on whether Bixlenvo generates meaningful sales and whether projected earnings growth is achieved.

Institutional Trading of Gilead Sciences

A number of hedge funds have recently added to or reduced their stakes in GILD. Aviva PLC increased its holdings in Gilead Sciences by 5.4% in the fourth quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock valued at $141,978,000 after purchasing an additional 59,782 shares during the period. Life Cycle Investment Partners Ltd acquired a new position in Gilead Sciences during the 4th quarter worth about $1,418,000. Bank of Nova Scotia bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at about $100,056,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at about $55,754,000. Finally, Harvest Fund Management Co. Ltd increased its stake in shares of Gilead Sciences by 14.4% in the fourth quarter. Harvest Fund Management Co. Ltd now owns 106,526 shares of the biopharmaceutical company’s stock valued at $13,075,000 after buying an additional 13,385 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.